» Articles » PMID: 11108158

Drug Delivery by the Intravaginal Route

Overview
Publisher Begell House
Specialty Pharmacology
Date 2000 Dec 7
PMID 11108158
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The human vagina represents a potential, accessible space that offers a valuable route for drug delivery through the use of specifically designed carrier systems for both local and systemic applications. Intravaginal drug delivery is particularly appropriate for drugs associated with women's health issues but may also have applications in general drug delivery within the female population. A range of drug delivery platforms suitable for intravaginal administration are discussed in this review, including hydrogels, vaginal tablets, pessaries/suppositories, particulate systems, and intravaginal rings. Drug release mechanisms and absorption pathways are reviewed with respect to a range of therapeutic and prophylactic indications for intravaginal delivery.

Citing Articles

Recent Advances in Studying In Vitro Drug Permeation Across Mucosal Membranes.

Song J, Xu Z, Xie L, Shen J Pharmaceutics. 2025; 17(2).

PMID: 40006623 PMC: 11858820. DOI: 10.3390/pharmaceutics17020256.


Recent Advances in the Excipients Used in Modified Release Vaginal Formulations.

Dedeloudi A, Siamidi A, Pavlou P, Vlachou M Materials (Basel). 2022; 15(1).

PMID: 35009472 PMC: 8745980. DOI: 10.3390/ma15010327.


In Vitro-In Vivo Correlation (IVIVC) Population Modeling for the In Silico Bioequivalence of a Long-Acting Release Formulation of Progesterone.

Tosca E, Rocchetti M, Perez E, Nieto C, Bettica P, Del Prado J Pharmaceutics. 2021; 13(2).

PMID: 33673306 PMC: 7918143. DOI: 10.3390/pharmaceutics13020255.


A thermosensitive gel based on w1/o/w2 multiple microemulsions for the vaginal delivery of small nucleic acid.

Wang J, Wang Y, Wang Z, Wang F, He J, Yang X Drug Deliv. 2019; 26(1):168-178.

PMID: 30822166 PMC: 6407577. DOI: 10.1080/10717544.2019.1568622.


Novel in situ gelling vaginal sponges of sildenafil citrate-based cubosomes for uterine targeting.

Aboud H, Hassan A, Ali A, Abdel-Razik A Drug Deliv. 2018; 25(1):1328-1339.

PMID: 29869515 PMC: 6058503. DOI: 10.1080/10717544.2018.1477858.